Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Abnormal chromosomes forecast leukemia relapse

17.06.2004


Patients with acute myeloid leukemia (AML) who enter remission with abnormal chromosomes in bone marrow cells are twice as vulnerable to recurrence of their disease as are AML patients with normal bone marrow cells at remission, according to a new study.



The findings by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute call for routine testing for chromosomal abnormalities in AML patients at diagnosis and again when patients enter remission.

If verified, the findings mean that AML patients showing chromosomal abnormalities early during remission should be considered for more intensive treatment, such as a bone marrow transplant, in an attempt to prevent a return of the disease. Patients with normal-looking chromosomes can receive standard therapy.


The findings are published in the June 15 issue of the Journal of Clinical Oncology.

“For the first time, we have shown in a relatively large group of patients that someone with AML who has abnormal chromosomes early during remission will relapse, even if blood counts and other parameters are favorable,” says first author Guido Marcucci, associate professor of internal medicine and a hematologist/oncologist with OSU’s James Cancer Hospital.

Since 1990, physicians have said that AML patients were in complete remission following treatment if their blood count was normal, and their bone marrow contained fewer than 5 percent of immature cells known as blasts.

By that definition, 60 percent to 70 percent of AML patients achieve complete remission, but only 30 percent to 40 percent of those patients remain in remission long enough to be considered completely cured of their disease.

“Achieving complete remission is an important step for a successful treatment,” Marcucci says, “but it does not predict who will do well in the long run and who will relapse. We need additional diagnostic indicators like the presence of abnormal chromosomes.”

The study of abnormal chromosomes is known as cytogenetics. Chromosomal, or cytogenetic, abnormalities are seen at diagnosis in about 55 percent of all AML patients. The remaining 45 percent have normal-looking chromosomes, or normal cytogenetics.

The presence of cytogenetic abnormalities at diagnosis has long proven to be one of the most important prognostic factors for AML. Furthermore, the sensitive technology and methods needed for cytogenetic testing, which were formerly found mainly in research laboratories, are now widely available for use in clinical tests.

This retrospective study examined the outcomes of 118 AML patients who had received cytogenetic testing at the time of diagnosis and at the first day of complete remission.

Of these, 103 patients had abnormal chromosomes at diagnosis and normal chromosomes at complete remission. These patients were compared to 15 others who had abnormal chromosomes at both diagnosis and at complete remission.

The results showed that patients with abnormal chromosomes at remission had a significantly shorter survival. They were twice as likely to relapse and die.

Based on their findings, the researchers concluded that converting from abnormal chromosomes to normal chromosomes at remission is an import predictor of long-term outcome in AML, and supports the use of cytogenetics testing at remission

“These findings indicate that the old definition of remission isn’t good enough,” Marcucci says. “We need to include cytogenetic complete remission as a criterion for complete remission in AML.”

Funding from the National Cancer Institute supported this research.


Contact: Darrell E. Ward, Medical Center Communications, 614-293-3737, or Ward-15@medctr.osu.edu

Darrell E. Ward | Ohio State University
Further information:
http://researchnews.osu.edu/archive/amlchrom.htm

More articles from Health and Medicine:

nachricht The genes are not to blame
20.07.2018 | Technische Universität München

nachricht Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>